Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  sipuleucel-T
Find trials that include:  Any drugs shown
Trial Status:  Closed
Results 1-13 of 13 for your search:
Start Over
Vaccine Therapy in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: D9901 CDR0000067868, DEN-D9901, NCI-G00-1789, NCT00005947
Provenge® (Sipuleucel-T) Active Cellular Immunotherapy Treatment of Metastatic Prostate Cancer After Failing Hormone Therapy
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: D9902B, UCLA-0307121-01, DEN-D9902B, NCT00065442
APC8015 and Bevacizumab in Treating Patients With Prostate Cancer
Phase: Phase II
Type: Treatment
Status: Completed
Age: Not specified
Sponsor: NCI
Protocol IDs: NCI-2012-02427, UCSF-0155-01, NCI-2617, UCSF-01554, CDR0000069047, 2617, NCT00027599
To Evaluate Sipuleucel-T Manufactured With Different Concentrations of Prostate Adenocarcinoma (PA2024) Antigen
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: P07-2, NCT00715078
Sipuleucel-T as Neoadjuvant Treatment in Prostate Cancer
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: P07-1, NCT00715104
Open Label Study of Sipuleucel-T
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: P09-1, NCT00901342
Sipuleucel-T in Metastatic Castrate Resistant Prostate Cancer (CRPC) Patients Previously Treated on Dendreon Study P-11 (NCT00779402)
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: P10-1, NCT01338012
Sequencing of Sipuleucel-T and ADT in Men With Non-metastatic Prostate Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: P10-2, NCT01431391
Sipuleucel-T Manufacturing Demonstration Study
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: P11-1, 2011-001192-39, NCT01477749
Concurrent Versus Sequential Treatment With Sipuleucel-T and Abiraterone in Men With Metastatic Castrate Resistant Prostate Cancer (mCRPC)
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: P11-3, NCT01487863
A Study of Sipuleucel-T With Administration of Enzalutamide in Men With Metastatic Castrate-Resistant Prostate Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: P12-2, NCT01981122
Sipuleucel-T and Ipilimumab for Advanced Prostate Cancer
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: SIPIPI 2013, NCT01832870
A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer
Phase: No phase specified
Type: Supportive care
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: P10-3, NCT01306890
Start Over